Sees revenue $16.4B-$16.8B, consensus $16.99B. Sees adjusted EBITDA $5B-$5.3B; FCF $2B-$2.4B. Francis continued: “Looking ahead, 2026 will be a milestone-rich year with multiple late-stage pipeline readouts across immunology and neurology; the anticipated FDA approval of olanzapine LAI, and important data expected for duvakitug, our anti-TL1A, and for our anti-IL-15 programs. Together, these pipeline assets represent a potential of over $10B reinforcing our confidence in Teva‘s (TEVA) ability to deliver durable, innovation-driven growth, creating real value for patients and shareholders alike.”
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA:
- Teva reports Q4 non-GAAP EPS 96c, consensus 64c
- Teva parnters iwth Will Forte to increase awareness of Huntington’s disease
- AI Daily: Nvidia invests $2B in CoreWeave
- Drugmakers use AI to help progress through trials, submissions, Reuters says
- Options Volatility and Implied Earnings Moves This Week, January 26 – January 30, 2026